{"id":7373,"date":"2025-02-14T13:50:00","date_gmt":"2025-02-14T12:50:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\/"},"modified":"2025-02-14T13:50:00","modified_gmt":"2025-02-14T12:50:00","slug":"valberedning-infor-arsstamman-2025-i-nanexa-ab-publ","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\/","title":{"rendered":"Valberedning inf\u00f6r \u00e5rsst\u00e4mman 2025 i Nanexa AB (publ)"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Valberedningen inf\u00f6r \u00e5rsst\u00e4mman 2025 i Nanexa AB (publ) har utsetts.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>Valberedningens ledam\u00f6ter utg\u00f6rs av:<\/p>\n<ul>\n<li>Marlon V\u00e4rnik, Exelity<\/li>\n<li>Jonas P\u00e5lsson<\/li>\n<li>G\u00f6ran Ando, styrelseordf\u00f6rande, adjungerad<\/li>\n<\/ul>\n<p>Valberedningens f\u00f6rslag kommer att presenteras i kallelsen till \u00e5rsst\u00e4mman 2025 samt p\u00e5 bolagets hemsida <a href=\"http:\/\/www.nanexa.com\/\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a>.<\/p>\n<p>Aktie\u00e4gare kan kontakta valberedningen med f\u00f6rslag avseende dess arbete genom att s\u00e4nda e-mail till <a href=\"mailto:info@nanexa.se\" rel=\"noopener\" target=\"_blank\">info@nanexa.se<\/a> (rubrik \u201dNanexas valberedning\u201d) eller via brev till Nanexa AB. Att: Nanexas valberedning, Virdings all\u00e9 2, SE-754 50 Uppsala.<\/p>\n<p>\u00c5rsst\u00e4mman kommer att h\u00e5llas i Uppsala den 15 maj 2025.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/9e4d0e65-cafe-471e-b31b-d4f98c5eef63\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ.pdf\" rel=\"noopener\" target=\"_blank\">Valberedning inf\u00f6r \u00e5rsst\u00e4mman 2025 i Nanexa AB (publ)<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Valberedningen inf\u00f6r \u00e5rsst\u00e4mman 2025 i Nanexa AB (publ) har utsetts.<\/p>\n","protected":false},"template":"","class_list":["post-7373","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv","mfn-news-tag-mfn-ci-nomination_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valberedning inf\u00f6r \u00e5rsst\u00e4mman 2025 i Nanexa AB (publ) - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valberedning inf\u00f6r \u00e5rsst\u00e4mman 2025 i Nanexa AB (publ) - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Valberedningen inf\u00f6r \u00e5rsst\u00e4mman 2025 i Nanexa AB (publ) har utsetts.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\\\/\",\"name\":\"Valberedning inf\u00f6r \u00e5rsst\u00e4mman 2025 i Nanexa AB (publ) - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2025-02-14T12:50:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Valberedning inf\u00f6r \u00e5rsst\u00e4mman 2025 i Nanexa AB (publ)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valberedning inf\u00f6r \u00e5rsst\u00e4mman 2025 i Nanexa AB (publ) - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\/","og_locale":"sv_SE","og_type":"article","og_title":"Valberedning inf\u00f6r \u00e5rsst\u00e4mman 2025 i Nanexa AB (publ) - Nanexa AB","og_description":"Valberedningen inf\u00f6r \u00e5rsst\u00e4mman 2025 i Nanexa AB (publ) har utsetts.","og_url":"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\/","url":"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\/","name":"Valberedning inf\u00f6r \u00e5rsst\u00e4mman 2025 i Nanexa AB (publ) - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2025-02-14T12:50:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-arsstamman-2025-i-nanexa-ab-publ\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Valberedning inf\u00f6r \u00e5rsst\u00e4mman 2025 i Nanexa AB (publ)"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}